| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Journal of Lipid Research, Vol. 46, 872-884, May 2005
Copyright © 2005 by American Society for Biochemistry and Molecular Biology
Cardiovascular Group, Antisense Drug Discovery, Isis Pharmaceuticals, Inc., 2292 Faraday Avenue, Carlsbad, CA 92008
1 To whom correspondence should be addressed. e-mail: rcrooke{at}isisph.com
High levels of plasma apolipoprotein B-100 (apoB-100), the principal apolipoprotein of LDL, are associated with cardiovascular disease. We hypothesized that suppression of apoB-100 mRNA by an antisense oligonucleotide (ASO) would reduce LDL cholesterol (LDL-C). Because most of the plasma apoB is made in the liver, and antisense drugs distribute to that organ, we tested the effects of a mouse-specific apoB-100 ASO in several mouse models of hyperlipidemia, including C57BL/6 mice fed a high-fat diet, Apoe-deficient mice, and Ldlr-deficient mice. The lead apoB-100 antisense compound, ISIS 147764, reduced apoB-100 mRNA levels in the liver and serum apoB-100 levels in a dose- and time-dependent manner. Consistent with those findings, total cholesterol and LDL-C decreased by 25–55% and 40–88%, respectively.
Unlike small-molecule inhibitors of microsomal triglyceride transfer protein, ISIS 147764 did not produce hepatic or intestinal steatosis and did not affect dietary fat absorption or elevate plasma transaminase levels. These findings, as well as those derived from interim phase I data with a human apoB-100 antisense drug, suggest that antisense inhibition of this target may be a safe and effective approach for the treatment of humans with hyperlipidemia.
Abbreviations: AMPK, AMP-activated protein kinase; apoB, apolipoprotein B; ASO, antisense oligonucleotide; G3PDH, glyceraldehyde-3-phosphate dehydrogenase; HF, high fat; LDL-C, LDL cholesterol; 2'MOE, 2'-O-methoxyethyl; MTP, microsomal triglyceride transfer protein; SCD, stearoyl CoA desaturase; SREBP, sterol-responsive element binding protein; SSC, standard sodium citrate; TG, triglyceride
Supplementary key words lipid metabolism • hypercholesterolemia • apoB-100 • apoB-48 • fat malabsorption • MTP inhibitors
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  L. A. Johnson, M. K. Altenburg, R. L. Walzem, L. T. Scanga, and N. Maeda Absence of Hyperlipidemia in LDL Receptor-Deficient Mice Having Apolipoprotein B100 Without the Putative Receptor-Binding Sequences Arterioscler. Thromb. Vasc. Biol., October 1, 2008; 28(10): 1745 - 1752. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Merki, M. J. Graham, A. E. Mullick, E. R. Miller, R. M. Crooke, R. E. Pitas, J. L. Witztum, and S. Tsimikas Antisense Oligonucleotide Directed to Human Apolipoprotein B-100 Reduces Lipoprotein(a) Levels and Oxidized Phospholipids on Human Apolipoprotein B-100 Particles in Lipoprotein(a) Transgenic Mice Circulation, August 12, 2008; 118(7): 743 - 753. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. X. Yu, S. F. Murray, L. Watts, S. L. Booten, J. Tokorcheck, B. P. Monia, and S. Bhanot Reduction of JNK1 expression with antisense oligonucleotide improves adiposity in obese mice Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E436 - E445. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. S. Peterson, L. G. Fong, and S. G. Young Errata. PCSK9 function and physiology J. Lipid Res., July 1, 2008; 49(7): 1595 - 1599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. S. Peterson, L. G. Fong, and S. G. Young PCSK9 function and physiology J. Lipid Res., June 1, 2008; 49(6): 1152 - 1156. [Full Text] [PDF]
|
|
|
|
 |
|
 V. Charlton-Menys and P. N. Durrington Human cholesterol metabolism and therapeutic molecules Exp Physiol, January 1, 2008; 93(1): 27 - 42. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. L. Hrizo, V. Gusarova, D. M. Habiel, J. L. Goeckeler, E. A. Fisher, and J. L. Brodsky The Hsp110 Molecular Chaperone Stabilizes Apolipoprotein B from Endoplasmic Reticulum-associated Degradation (ERAD) J. Biol. Chem., November 9, 2007; 282(45): 32665 - 32675. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. K Ito ISIS 301012 Gene Therapy for Hypercholesterolemia: Sense, Antisense, or Nonsense? Ann. Pharmacother., October 1, 2007; 41(10): 1669 - 1678. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. B. Rozema, D. L. Lewis, D. H. Wakefield, S. C. Wong, J. J. Klein, P. L. Roesch, S. L. Bertin, T. W. Reppen, Q. Chu, A. V. Blokhin, et al. Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytes PNAS, August 7, 2007; 104(32): 12982 - 12987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Choi, D. B. Savage, A. Kulkarni, X. X. Yu, Z.-X. Liu, K. Morino, S. Kim, A. Distefano, V. T. Samuel, S. Neschen, et al. Suppression of Diacylglycerol Acyltransferase-2 (DGAT2), but Not DGAT1, with Antisense Oligonucleotides Reverses Diet-induced Hepatic Steatosis and Insulin Resistance J. Biol. Chem., August 3, 2007; 282(31): 22678 - 22688. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. Sloop, A. D. Showalter, A. L. Cox, J. X. C. Cao, A. M. Siesky, H. Y. Zhang, A. R. Irizarry, S. F. Murray, S. L. Booten, E. A. Finger, et al. Specific Reduction of Hepatic Glucose 6-Phosphate Transporter-1 Ameliorates Diabetes while Avoiding Complications of Glycogen Storage Disease J. Biol. Chem., June 29, 2007; 282(26): 19113 - 19121. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Larosche, P. Letteron, B. Fromenty, N. Vadrot, A. Abbey-Toby, G. Feldmann, D. Pessayre, and A. Mansouri Tamoxifen Inhibits Topoisomerases, Depletes Mitochondrial DNA, and Triggers Steatosis in Mouse Liver J. Pharmacol. Exp. Ther., May 1, 2007; 321(2): 526 - 535. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Graham, K. M. Lemonidis, C. P. Whipple, A. Subramaniam, B. P. Monia, S. T. Crooke, and R. M. Crooke Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice J. Lipid Res., April 1, 2007; 48(4): 763 - 767. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Z. Yu, T.-W. Kim, A. Hong, T. A. Watanabe, H. J. Gaus, and R. S. Geary Cross-Species Pharmacokinetic Comparison from Mouse to Man of a Second-Generation Antisense Oligonucleotide, ISIS 301012, Targeting Human Apolipoprotein B-100 Drug Metab. Dispos., March 1, 2007; 35(3): 460 - 468. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Swayze, A. M. Siwkowski, E. V. Wancewicz, M. T. Migawa, T. K. Wyrzykiewicz, G. Hung, B. P. Monia, and a. C. F. Bennett Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals Nucleic Acids Res., January 28, 2007; 35(2): 687 - 700. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J.P. Kastelein, M. K. Wedel, B. F. Baker, J. Su, J. D. Bradley, R. Z. Yu, E. Chuang, M. J. Graham, and R. M. Crooke Potent Reduction of Apolipoprotein B and Low-Density Lipoprotein Cholesterol by Short-Term Administration of an Antisense Inhibitor of Apolipoprotein B Circulation, October 17, 2006; 114(16): 1729 - 1735. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. V. Farese Jr The nine lives of ACAT inhibitors. Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1684 - 1686. [Full Text] [PDF]
|
|
|
|
|
|
T. A. Bell III, J. M. Brown, M. J. Graham, K. M. Lemonidis, R. M. Crooke, and L. L. Rudel Liver-Specific Inhibition of Acyl-Coenzyme A:Cholesterol Acyltransferase 2 With Antisense Oligonucleotides Limits Atherosclerosis Development in Apolipoprotein B100-Only Low-Density Lipoprotein Receptor-/- Mice Arterioscler. Thromb. Vasc. Biol., August 1, 2006; 26(8): 1814 - 1820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Rava, G. K. Ojakian, G. S. Shelness, and M. M. Hussain Phospholipid Transfer Activity of Microsomal Triacylglycerol Transfer Protein Is Sufficient for the Assembly and Secretion of Apolipoprotein B Lipoproteins J. Biol. Chem., April 21, 2006; 281(16): 11019 - 11027. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G Tachas, S Lofthouse, C J Wraight, B F Baker, N B Sioufi, R A Jarres, A Berdeja, A M Rao, L M Kerr, E M d'Aniello, et al. A GH receptor antisense oligonucleotide inhibits hepatic GH receptor expression, IGF-I production and body weight gain in normal mice. J. Endocrinol., April 1, 2006; 189(1): 147 - 154. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Torzewski C-Reactive Protein and Atherogenesis: New Insights from Established Animal Models Am. J. Pathol., October 1, 2005; 167(4): 923 - 925. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Journal of Biological Chemistry |
| Molecular and Cellular Proteomics | ASBMB Today |
